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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease primarily
characterized by loss of motor neurons in brain and spinal cord. The death of motor
neurons leads to denervation of muscle which in turn causes muscle weakness
and paralysis, decreased respiratory function and eventually death. Growing evidence
indicates disturbances in energy metabolism in patients with ALS and animal models
of ALS, which are likely to contribute to disease progression. Particularly, defects in
glucose metabolism and mitochondrial dysfunction limit the availability of ATP to CNS
tissues and muscle. Several metabolic approaches improving mitochondrial function
have been investigated in vitro and in vivo and showed varying effects in ALS. The effects
of metabolic approaches in ALS models encompass delays in onset of motor symptoms,
protection of motor neurons and extension of survival, which signifies an important role
of metabolism in the pathogenesis of the disease. There is now an urgent need to test
metabolic approaches in controlled clinical trials. In addition, more detailed studies to
better characterize the abnormalities in energy metabolism in patients with ALS and ALS
models are necessary to develop metabolically targeted effective therapies that can slow
the progression of the disease and prolong life for patients with ALS.
Keywords: amyotrophic lateral sclerosis, energy metabolism, medium chain fatty acids, mitochondria, metabolic
treatment
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a complex multi-pathogenic neurodegenerative disorder
primarily characterized by the loss of upper motor neurons in the brain and lower motor neurons
in the spinal cord and the brain stem (Robberecht and Philips, 2013). As a result of this neuronal
loss, motor function declines progressively which then leads to impairments in respiratory function
and eventually death within 2–5 years of diagnosis (Kiernan et al., 2011). The exact mechanisms
underlying the selective loss of motor neurons in the disease are not yet known. However, several
mechanisms appear to contribute, including glutamate excitotoxicity (Rothstein et al., 1990),
oxidative stress (Barber et al., 2006), protein aggregation (Rosen et al., 1993; Bruijn et al., 1998),
cytoskeletal and axonal transport abnormalities (Julien and Beaulieu, 2000), inflammation (Julien
and Beaulieu, 2000), hyperexcitability (Zanette et al., 2002; Vucic and Kiernan, 2006; Vucic et al.,
2008) and altered energy metabolism (Dupuis et al., 2004, 2011). It is believed that several of these
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mechanisms are interconnected and together are responsible for
the progression of the disease. To date, there is only one approved
medication available to treat ALS, namely riluzole, which only
increases survival by 3months (Bensimon et al., 1994). Therefore,
it is imperative to look for other potential treatments that can halt
the progression of the disease and extend life. In this review, we
discuss impairments in energy metabolism in ALS and review the
effects of metabolic therapies investigated so far in animal models
of ALS and/or patients with ALS.
ENERGY METABOLISM DISTURBANCES
IN ALS
There are many lines of evidence for the role of disturbed
energy metabolism in ALS pathogenesis. Energy homeostasis,
the balance between energy intake and expenditure, appears to
be compromised in patients with ALS (Dupuis et al., 2011).
Besides, some patients exhibit hypermetabolism (an increased
metabolism at rest) (Kasarskis et al., 1996; Desport et al., 2001;
Bouteloup et al., 2009; Marin et al., 2011), body weight loss
(Körner et al., 2013b) and abnormalmetabolism of lipids (Dupuis
et al., 2011), which are likely to contribute to disease. These
and many studies discussed below reveal problems in energy
metabolism in whole tissues and even the whole organism. It
is not entirely clear to which extent the metabolic changes
found in ALS patients and ALS models only arise as a result of
neurodegeneration. Moreover, little is known about the specific
metabolic changes within the motor neurons themselves and if
they contribute to the degeneration. Other early reviews discuss
reasons for the specific degeneration of motor neurons in ALS
(Shaw and Eggett, 2000; Cleveland and Rothstein, 2001).
Specific Dysfunctions in Energy Producing
Pathways in ALS
Under normal physiological conditions, glucose is the main
energy substrate for neuronal tissue and a major fuel for
muscles. However, there are indications of defects in the glucose
metabolizing pathways in ALS namely in the glycolysis and the
TCA cycle pathways in CNS and muscle (Palamiuc et al., 2015;
Tefera et al., 2016). In addition, there is decreased glucose uptake
in numerous brain regions and spinal cord of animal models
and patients with ALS (Dalakas et al., 1987; Hatazawa et al.,
1988; Ludolph et al., 1992; Browne et al., 2006; Miyazaki et al.,
2012; Cistaro et al., 2014). In muscle, namely the tibialis anterior
muscle of the superoxide dismutase 1 (SOD1G86R) mice, the
activities of the enzyme phosphofructokinase 1 (PFK1), the rate
limiting enzyme in glycolysis, were reduced (Palamiuc et al.,
2015). Furthermore, in the gastrocnemius muscle of SOD1G93A
mice, the activities of the TCA cycle enzyme 2-oxoglutarate
dehydrogenase (OGDH) were found to be reduced in the late
symptomatic phases of the disease, indicating impairments in the
TCA cycle pathway (Tefera et al., 2016). Furthermore, changes
in the expression of several genes involved in energy metabolism
have been observed in muscle, brain and spinal cord tissues
and cells isolated from them. Particularly, genes involved in the
mitochondrial electron transport chain are significantly altered
(Ferraiuolo et al., 2007, 2011; Lederer et al., 2007; Raman et al.,
2015). Mitochondria are the main site of energy production
and they are also the main sites for the generation of reactive
oxygen species. Compromised mitochondrial function has been
recognized for a long time in many neurodegenerative disorders,
which is expected to lead to reduced production of ATP and
increased oxidative stress (Cozzolino and Carrì, 2012). Similarly
in ALS, numerous studies have shown functional and structural
abnormalities in mitochondria that give rise to reduced oxidative
phosphorylation and subsequent decreased generation of ATP
(Jung et al., 2002; Mattiazzi et al., 2002; Menzies et al., 2002;
Wiedemann et al., 2002; Browne et al., 2006). In addition, in vitro
studies showed that mitochondrial dysfunction in astrocytes may
lead to generation of free radicals and release of toxic factors
that could contribute to motor neuron dysfunction (Nagai et al.,
2007; Cassina et al., 2008). In conclusion, pathological changes in
the energy metabolizing pathways that lead to deficiency in ATP
production and/or utilization may contribute to progression of
the disease.
Role of Glial Cells in Metabolism and ALS
Although ALS is mainly characterized by the selective loss
of motor neurons, neighboring non-neuronal cells such as
astrocytes (Clement et al., 2003; Nagai et al., 2007), microglia
(Beers et al., 2006; Boillée et al., 2006b) and oligodendrocytes
(Yamanaka et al., 2008; Lee et al., 2012; Kang et al., 2013)
can contribute to the progression of the disease (reviewed by
Boillée et al., 2006a). The metabolic coupling between neurons
and astrocytes has long been known. During neurotransmission,
neurons release glutamate into the synapse which can be taken
up by astrocytes. It is then metabolized to glutamine, which
can be supplied to neurons to resynthesize glutamate. Many
immunohistochemical studies have shown the loss of glutamate
transporters in astrocytes in spinal cord and brain of patients
with ALS (Rothstein et al., 1995; Fray et al., 1998; Sasaki et al.,
2000). Deficiencies in glutamate uptake and the glutamate-
glutamine cycle can lead to problems in neuronal signaling and
promotes excitotoxicity (reviewed by Danbolt, 2001; Van Den
Bosch et al., 2006). In addition, according to the astrocyte-neuron
lactate shuttle hypothesis, glutamate stimulated metabolism of
glucose in astrocytes produces lactate which can be transferred
to neurons to be utilized as fuel (Pellerin and Magistretti,
1994). Altered gene expression of the astrocytic lactate eﬄux
transporter (monocarboxylate transporter 4, SLC16A4) together
with reduced lactate levels found in the spinal cord of hSOD1G93A
mice further suggest that metabolic interaction between neurons
and astrocytes may be disrupted in ALS (Ferraiuolo et al., 2011).
The potential of metabolic coupling between neurons and
oligodendrocytes has gained a lot of interest in recent years and
it appears that oligodendrocytes also can release lactate. Recent
studies displayed the involvement of oligodendrocytes in the
pathogenesis of ALS (Lee et al., 2012; Kang et al., 2013; Philips
et al., 2013). Healthy oligodendrocytes can metabolically support
neurons by providing energy metabolites via monocarboxylate
transporters (Fünfschilling et al., 2012; Lee et al., 2012; Morrison
et al., 2013). In contrast, the transport of glycolytic substrates
such as lactate from oligodendrocytes to neurons is found
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to be disrupted in SOD1G93A mice spinal cord (Lee et al.,
2012; Kang et al., 2013). Consistent with this, the expressions
of the oligodendrocytic lactate transporter monocarboxylate
transporter 1 (SLC16A1) was decreased in the spinal cords of
patients with ALS and SOD1G93A mice (Lee et al., 2012; Philips
et al., 2013) suggesting abnormalities in lactate transfer.
In addition to astrocytes and oligodendrocytes, microglia
have been shown to be involved in ALS pathogenesis (Beers
et al., 2006; Boillée et al., 2006b). Microglia are immune cells
within the CNS, similar to macrophages, which can either have a
neuroprotective or a neurotoxic role during ALS progression. It is
believed that microglia protect neurons early in the disease stage.
However, as the disease progresses, activated microglia can be
pro-inflammatory and neurotoxic (Appel et al., 2011; Dibaj et al.,
2011). In vivo imaging studies demonstrated increased microglia
activation and inflammatory activity in spinal cord during
symptomatic stages in the SOD1G93A mouse model (Dibaj et al.,
2011). Reduced expression of mutant SOD1 in microglia delayed
late disease progression and increased survival of SOD1G37R mice
(Boillée et al., 2006b). In conclusion, perturbations in glial cells
can affect neurons and directly or indirectly can contribute to
energy deficits in neurons. The studies discussed demonstrate
the importance of non-neuronal cells in supporting neurons in
various ways and indicate that abnormalities in glial cells can
exacerbate the progression of the disease.
High Calorie Diets in ALS
A number of studies have tried to correct the energy deficit using
metabolic therapies in animalmodels and patients with ALS, with
the hope that an improved metabolism can delay symptoms and
extend survival in ALS (Dupuis et al., 2004; Zhao et al., 2006,
2012; Mattson et al., 2007; Miquel et al., 2012; Ari et al., 2014;
Wills et al., 2014; Palamiuc et al., 2015; Tefera et al., 2016). A study
by Dupuis et al. (2004) in SOD1G86R mice found aberrations
of energy metabolism such as reduction of adiposity, increased
energy expenditure and lipolysis, and examined the effects of a
high fat diet that consisted of regular chow supplemented with
21% (wt/wt) butter fat and 0.15% (wt/wt) cholesterol. A 20%
increase in the mean survival of these mice compared to mice
fed with control diet was demonstrated and motor neuron loss
was reduced. Moreover, SOD1G93A mice fed either a high fat diet
(containing 47% fat, 38% carbohydrates and 15% protein) or with
control diet (constituting 17% fats, 64% carbohydrates and 19%
protein) starting at 6 weeks of age also showed an increase in
survival and the onset of motor symptoms and weight loss were
delayed significantly. While mice treated with control diet died
by 180 days, high fat died treated mice survived until 220 days
and some of them survived more than 270 days (Mattson et al.,
2007). On a similar note, several studies have alluded that body
mass index is strongly correlated with survival of patients with
ALS (reviewed in Ngo et al., 2014). A prospective study of over
a million people for about 14–28 years demonstrated that obese
people have a 30–40% lower risk of developing ALS compared
to those with a healthy weight (O’Reilly et al., 2013). Given the
strong link found between low body mass index and decreased
survival with ALS (Paganoni et al., 2011), a randomized double
blind phase 2 clinical study was performed in small number of
patients with ALS to test the safety and tolerability of high caloric
diets, which were either high in carbohydrates or high in fat.
Compared to an isocaloric control diet, the high carbohydrate-
high calorie diet was safe, tolerable and effective in delaying
weight loss and prolonging survival in the patients (Wills et al.,
2014). Further large scale trials are needed to corroborate these
promising effects. Also due to the small sample size, a beneficial
effect of a high fat high calorie diet cannot yet be ruled out
completely. On the other hand, high fat diets are linked with side
effects such as brain inflammation, cognitive deficits, and anxiety
and depressive behaviors (Zhang et al., 2005; Pistell et al., 2010;
Dutheil et al., 2016). Together, these studies show the importance
of adequate energy supply to slow the progression of ALS.
METABOLIC TREATMENTS IN ALS
Given that defects in energy metabolism are evident in ALS,
addressing these disturbances is a reasonable approach to
improve quality of life and prolong survival in patients with
ALS. Because of the impairments found in glucose metabolism
together with the increased energy demand in neurons and
muscles, additional fuel appears to be important. To increase
energy uptake, additional alternative metabolic fuels for the CNS
and muscle also appear warranted and could include ketones
and medium chain fats, but also metabolic intermediates, such
as pyruvate, lactate, α-ketoglutarate and others. Moreover,
compounds that can enhance mitochondrial function to generate
more energy are expected to ameliorate disease progression.
This includes substances that improve mitochondrial function
by inhibiting oxidative stress or stabilizing mitochondrial
membranes. There are also supplements that provide energy
substrates that can refill deficient C4 carbon TCA cycle
intermediates (anaplerosis), which thereby will improve
oxidative phosphorylation of any fuel in addition to providing
alternative fuel. This includes triheptanoin and α-ketoglutarate.
Consistent with these theoretical notions, alternative fuels,
metabolic supplements and mitochondrial function enhancers
have been investigated with the purpose of improving ALS
symptoms and delaying disease progression in mouse
models of ALS, cell cultures and in patients with ALS.
These metabolic potential treatments include triheptanoin,
ketogenic diet, caprylic triglyceride, dichloroacetate, the Deanna
protocol, pyruvate, lactate, creatine, coenzyme Q10, MitoQ,
dexpramipexole, acetyl-L-carnitine and olesoxime, which we
will discuss below. Their mechanisms and effects are also
summarized in Figure 1.
Triheptanoin
Triheptanoin is an alternative fuel, which can also boost the
metabolism of other fuels by refilling deficient C4 TCA cycle
metabolites and is therefore ideal for disorders with high
energy needs. Triheptanoin is a medium chain triglyceride
(MCT) containing the odd chain C7 fatty acid heptanoate.
After hydrolysis in the gastro-intestinal tract, medium chain
fatty acids diffuse into cells, the blood stream and into
mitochondria. This enhances their availability to various organs
including the CNS and muscles. In contrast, long chain fatty
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FIGURE 1 | Summary of cellular mechanisms of metabolic approaches in ALS. Under normal physiological conditions, glucose is the main fuel for CNS or
muscle cells and is metabolized via glycolysis into two molecules of pyruvate in the cytosol (purple background). Pyruvate can be converted by pyruvate
dehydrogenase (PDH) into acetyl CoA in the mitochondria (light blue background), which enters the TCA cycle by condensing with oxaloacetate (OAA) to form citrate.
Citrate gets further metabolized to generate NADH and ATP. Lactate is a glycolytic product that can be used to provide energy. According to the lactate shuttle
hypothesis, lactate can also be transported into the mitochondria via monocarboxylate transporters and then get converted to pyruvate to enter the TCA cycle. In
ALS, where energy demand is high and glucose metabolism is defective, alternative fuels can be provided by the ketogenic diet producing C4 ketones and the
medium chain triglycerides (MCT). Among the MCTs, caprylic triglyceride is metabolized to C4 ketones and caprylic acid and triheptanoin provides heptanoate and C5
ketones, which all can be taken up from the blood and used by the CNS and muscle cells. The C4 and C5 ketones as well as caprylic acid are converted into
acetyl-CoA and enter the TCA cycle. Increased C4 ketone levels can also activate astrocytes and facilitate conversion of glutamate into glutamine. This further
provides more glutamine for the synthesis of GABA and less conversion of glutamate to aspartate (blue arrows, see section The Ketogenic Diet and Caprylic
Triglyceride). Triheptanoin provides three molecules of heptanoate (green arrows), which can be converted into C5 ketones in the liver. Heptanoate and C5 ketones
can enter the brain and muscle to be metabolized to acetyl-CoA and propionyl CoA. Propionyl CoA is an anaplerotic molecule that can be further converted into
succinyl-CoA and enter into the TCA cycle. This restores (lost) C4 TCA cycle intermediate levels and promotes TCA cycling. Dichloroacetate is a PDH kinase inhibitor,
which activates PDH thereby increasing the entry of pyruvate into the TCA cycle. Creatine provides high energy phosphates and stabilizes membranes and hence
enhances mitochondrial function. The mitochondrial targeted antioxidants CoQ10, MitoQ and dexpramipexole promote mitochondrial energy generation. Olesoxime
stabilizes mitochondrial membrane permeability transition pores. The Deanna protocol is a combination of supplements that can provide acetyl CoA and
intermediates, such as α-ketoglutarate (α-KG) that feed into the TCA cycle (purple dashed arrows).
acids are bound to plasma proteins and require transporter
proteins for uptake into cells and mitochondria (Schönfeld
and Wojtczak, 2016). When heptanoate is metabolized by β-
oxidation, it generates two molecules of acetyl-CoA and one
molecule of propionyl-CoA. In the liver, heptanoate can form
the C5 ketones, β-ketopentanoate and β-hydroxypentanoate,
which are released into the blood and can be taken up by
neuronal and other cells through monocarboxylate transporters.
Similar to heptanoate, the C5 ketones give rise to acetyl-
CoA and propionyl-CoA. Propionyl-CoA enters the TCA cycle
after it is carboxylated by propionyl-CoA carboxylase and then
metabolized to succinyl-CoA, thereby (re-) filling the (deficient)
C4 TCA cycle intermediate pool (reviewed in Brunengraber
and Roe, 2006). C4 TCA cycle intermediates contribute to the
formation of oxaloacetate, which is needed to condense with
acetyl-CoA to citrate. Thus, overall heptanoate and C5 ketones
provide additional alternative fuel to form acetyl-CoA and by
increasing the levels of oxaloacetate improve acetyl-CoA entry
into the TCA cycle, required for aerobic ATP production. The
ability of triheptanoin to provide both acetyl-CoA and propionyl-
CoA makes it an ideal metabolic treatment for disorders with
deficient levels of TCA cycle intermediates and impairments
in energy production. For instance, triheptanoin alleviated
metabolic disturbances associated with several neurological and
neuromuscular disorders and improved symptoms in models of
epilepsy (Willis et al., 2010; Thomas et al., 2012; Hadera et al.,
2014), Canavan disease (Francis et al., 2014), autism disorders
(Park et al., 2014) and Alzheimer’s Disease (Aso et al., 2013)
as well as patients and a mouse model of glucose transporter
1 deficiency (Marin-Valencia et al., 2013; Pascual et al., 2014;
Mochel et al., 2016), and patients with Huntington’s disease
(Mochel et al., 2010; Adanyeguh et al., 2015). In chronically
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“epileptic” mice it was shown that triheptanoin partially restores
reduced TCA cycle intermediate and metabolite levels (Willis
et al., 2010; Hadera et al., 2014). Cognisant of the positive effects
of triheptanoin in other brain and neuromuscular disorders and
its mechanism of action, we hypothesized that treatment with
triheptanoin, being an alternative substrate to glucose provides
degenerating cells with much needed energy, which can delay
cell death and thereby the onset of motor symptoms in the
ALS mouse model. Thus we recently investigated the effects of
triheptanoin in the hSOD1G93A mice (Tefera et al., 2016).
We first showed that in the gastrocnemius muscle of
the hSOD1G93A mice, gene expression of enzymes involved
in the glycolysis, TCA cycle and anaplerotic pathways such
as glyceraldehyde-3-phosphate dehydrogenase, pyruvate, 2-
oxoglutarate and succinate dehydrogenases, at earlier (10 weeks)
and at later symptomatic stages (25 weeks) of the disease was
reduced. Downregulation of these metabolic enzymes in muscle
even at early stages where grip strength was still intact suggests
that metabolic defects in the energy producing pathways could
contribute to disease progression in ALS (Tefera et al., 2016). We
also found reduced activities of 2-oxoglutarate dehydrogenase
enzyme at the late stage of the disease (25 weeks) indicating
abnormalities in the TCA cycle pathway. We then showed
that treatment of hSOD1G93A mice with triheptanoin (where
35% of calories were from this oil, 17% w/diet w) from
P35 until P70 prevented downregulation of the enzymes such
as succinate dehydrogenase, glutamic pyruvic transaminase 2
and the propionyl carboxylase β subunit compared to mice
treated with control diet. Similarly, treatment with triheptanoin
protected against motor neuron loss by 33% in the lumbar spinal
cord (Tefera et al., 2016). It also delayed the onset of motor
symptoms which was shown by improvements in grip strength
and rotarod tests. It is believed that the neuroprotective effects
of triheptanoin due to increased ATP generation contribute
to improvements in motor function. In addition, increased
ATP generation in remaining neurons and muscle is likely to
also benefit motor function. Please note that our study was
underpowered to determine changes in survival. It remains to be
seen if triheptanoin is effective in other rodent ALS models and if
it can be tolerated by patients with ALS.
The Ketogenic Diet and Caprylic
Triglyceride
Ketogenic diets consist of extremely high amounts of fats, while
carbohydrates and proteins are restricted. They are successfully
used for the treatment of childhood epilepsies, where several
controlled clinical trials have now shown efficacy (Martin et al.,
2016) and there is also some efficacy against seizures in adults.
Ketogenic diets are now being tested in a variety of disorders,
including some characterized by neurodegeneration, such as
Alzheimer’s Disease (Van der Auwera et al., 2005; Henderson
et al., 2009) and traumatic brain (Prins et al., 2005; Appelberg
et al., 2009; Hu et al., 2009b; Deng-Bryant et al., 2011) and
spinal injury (Streijger et al., 2013). Administration of ketones
after controlled cortical impact injury in young rats reduced
lesion volume, attenuated motor and cognitive deficits, reduced
cellular apoptotic markers, and improved cerebral ATP levels
(Prins et al., 2005; Appelberg et al., 2009; Hu et al., 2009a,b;
Deng-Bryant et al., 2011). Also, BHB was able to rescue neurons
from degeneration, alleviate motor deficits against 1-Methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity, and improve
mitochondrial ATP generation (Tieu et al., 2003). Similarly,
it improved cerebral energy metabolism in ischemic rat brain
(Suzuki et al., 2001) and prevented glutamate mediated neuronal
toxicity and lipid peroxidation (Mejía-Toiber et al., 2006). While
on a ketogenic diet, blood glucose levels remain consistently in
the lower part of the normal range and the liver produces the C4
ketones, β-hydroxy butyrate (BHB) and aceto-acetate, which are
secreted into the blood. If C4 ketones are available, the CNS will
use C4 ketones as fuel preferably to glucose (Courchesne-Loyer
et al., 2016).
In SOD1G93A mice, a ketogenic diet was shown to protect
against the loss of motor neurons in the spinal cord and to
delay the onset of behavioral symptoms (Zhao et al., 2006).
BHB was also able to increase the rate of ATP generation in
mitochondria isolated from the spinal cord of SOD1G93A mice
as well as in cultured spinal cord neurons from these mice
in the presence of rotenone (Zhao et al., 2006). Mechanisms
by which the ketogenic diet modifies disease progression are
probably multifold (Masino and Rho, 2012). Most likely the
use of C4 ketones as alternative fuels as well as their anti-
oxidant and anti-inflammatory effects plays important roles.
Moreover, C4 ketones can alter metabolism in the brain. It has
been hypothesized that ketones activate astrocytes and hence
increases the conversion of glutamate to glutamine by glutamine
synthetase thereby reducing the availability of glutamate in
the synapse (Yudkoff et al., 2008). This reduces glutamate
excitotoxicity, which is one of the mechanisms most likely
involved in the pathogenesis of ALS (Rothstein et al., 1990).
Moreover, according to the glutamate-glutamine-GABA cycle,
astrocytes release glutamine to neurons and inhibitory neurons
convert it to GABA. Thus, more glutamine in astrocytes may
also lead to increased availability of glutamate for the synthesis
of GABA, the primary inhibitory neurotransmitter in the brain
(Yudkoff et al., 2008). It is also hypothesized that this leads to
less glutamate available to produce aspartate, another excitatory
neurotransmitter in the brain (Yudkoff et al., 2008). Cortical
hyperexcitability due to reduced intracortical inhibition has
been shown in patients with ALS and preceded the onset of
ALS symptoms (Vucic and Kiernan, 2006; Vucic et al., 2008).
Reductions in GABA levels found in patients with ALS in motor
cortex compared to healthy controls (Foerster et al., 2012, 2013)
may contribute to cortical hyperexcitability. Similarly, in the
cortex of wobbler mouse model of ALS, reduced GABAmediated
inhibition in the layer 5 pyramidal neurons as a result of loss
of GABAergic interneurons was shown, resulting in cortical
excitability (Nieto-Gonzalez et al., 2011).
The MCT of eight carbon octanoate, caprylic triglyceride,
has also been investigated (Zhao et al., 2012). After hydrolysis
of the ester bonds, octanoic (caprylic) acid can be metabolized
quickly by β-oxidation to acetyl CoA and C4 ketone bodies to
supply the TCA cycle. As mentioned above, one advantage of
medium chain fatty acids is that they are able to easily diffuse
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through plasma as well as mitochondrial membranes and do
not require transport proteins (Schönfeld and Wojtczak, 2016).
Thus, MCTs can serve as a fast fuel especially in conditions
with decreased uptake of glucose. In SOD1G93A mice, feeding
10% (w/w) caprylic triglyceride improved motor performance
in the rotarod test, protected against motor neuron loss and
increased oxygen consumption in mitochondria isolated from
the spinal cord (Zhao et al., 2012). Please note that this MCT
dose is not very high and blood ketone levels were unchanged
in the presymptomatic phase and only about doubled in the
postsymptomatic phase in SOD1G93A mice. In comparison while
on ketogenic diet the levels quadrupled in the same mouse strain
(Zhao et al., 2006). This may indicate that octanoate itself may be
sufficient for neuroprotection and ketone formation may not be
necessary.
Disappointingly, neither the ketogenic diet nor caprylic
triglyceride improved the survival of SOD1G93A mice (Zhao
et al., 2006, 2012). Also, it is important to note that in
other studies octanoate limited glucose metabolism in rodents
(Wlaz et al., 2012; McDonald et al., 2014). Given that glucose
utilization is compromised in ALS, further inhibiting glucose
metabolism may worsen disease progression. Last, ketogenic
diets are associated with loss of body weight, which in ALS can
worsen disease progression. Thus, these apparently successful
metabolic approaches in this ALS mouse model cannot be fully
recommended for ALS patients.
The Deanna Protocol
The Deanna protocol is a combination of nutritional
supplements containing energy supplements, vitamins, and
antioxidants such as glutathione, nicotinamide adenine
dinucleotide (NADH), coenzyme Q10 (CoQ10) and ubiquinol in
addition to MCTs if tolerated. It was claimed to have beneficial
effects in anecdotal reports (Fournier et al., 2013). The effects
of the main constituents of the supplement, including arginine
α-ketoglutarate (AAKG), MCT rich in caprylic triglyceride
and GABA, were tested in SOD1G93A mice (Ari et al., 2014).
AAKG provides α-ketoglutarate, which is taken up by sodium-
dependent transport carriers into synaptosomes and can be
incorporated into the TCA cycle (Shank and Campbell, 1981,
1984). In addition, the medium chain fats can be rapidly
metabolized and easily diffuse into mitochondria to provide
acetyl CoA. Ari and colleagues showed that this simplified
metabolic treatment delayed motor symptoms and increased
survival in SOD1G93A mice (Ari et al., 2014). In our opinion,
the true effects of the Deanna protocol in patients with ALS are
worthwhile to be studied. However, this will be very difficult,
because most patients take dietary supplements and vitamins.
Dichloroacetate
Dichloroacetate (DCA) is a pyruvate dehydrogenase (PDH)
kinase inhibitor (Whitehouse et al., 1974). Inhibition of PDH
kinase leads to less phosphorylation of PDH resulting in
activation of this enzyme that catalyzes the conversion of
pyruvate to acetyl CoA (McAllister et al., 1973). Thus, DCA
facilitates oxidation of glucose and generation of ATP in the
mitochondria (Itoh et al., 2003). The effects of DCA were
examined in the SOD1G93A mouse model of ALS (Miquel
et al., 2012). DCA prevented the toxicity of astrocytes to
motor neurons in neuron-astrocyte co-cultures from SOD1G93A
rat spinal cord. In addition, when DCA was administered to
SOD1G93A mice starting at 10 weeks; it reduced motor neuron
loss in the lumbar spinal cord by 25%, delayed onset of ALS
motor symptoms in a grip strength test and improved survival
(Miquel et al., 2012). The mechanism by which it modifies
disease progression is believed to be improved astrocytic TCA
cycling and mitochondrial function (Miquel et al., 2012). In
another similar study by Palamiuc et al. (2015) in SOD1G86R
mice, the protective effects of DCA were corroborated. In this
study, DCA improved grip strength performance, prevented
downregulation of mitochondrial genes, and protected against
muscle denervation. At doses used inmetabolic studies, DCAwas
well tolerated in patients with brain cancers (Dunbar et al., 2014).
Its safety, tolerability and efficacy in ALS patients remain to be
studied.
Pyruvate
Pyruvate is a glycolytic metabolite that can enter the TCA
cycle following its conversion into acetyl CoA. It was shown to
be neuroprotective in cultured mouse striatal neurons against
N-methyl D-aspartate (NMDA) and H2O2 mediated toxicity
(Desagher et al., 1997; Maus et al., 1999) and in cortical neuronal
cultures subjected to oxygen-glucose deprivation by improving
cellular energy metabolism, reducing reactive oxygen species
levels and anti-inflammatory mechanisms (Shen et al., 2010;
Pan et al., 2012). Pyruvate’s ability to protect cortical neurons
against H2O2 toxicity involves monocarboxylate transporters
(Nakamichi et al., 2005). In juvenile rat hippocampal slices,
pyruvate administration was able to restore ATP levels and rescue
neurons against NMDA mediated excitotoxicity (Izumi and
Zorumski, 2010). Pyruvate treatment reduced infarct size and
improved neurological functions in a rat middle cerebral artery
occlusion model of ischemia (Yu et al., 2005). It also improved
cerebral oxidative metabolism and neurological outcomes in rats
following cortical contusion injury (Fukushima et al., 2009; Moro
and Sutton, 2010), protected againstMPTP induced degeneration
of neurons and reduced oxidative stress in a mouse model of
Parkinson’s disease (Huh et al., 2011; Satpute et al., 2013), and
reduced cognitive deficits in a mouse model of Alzheimer’s
disease (Isopi et al., 2015).
In the SOD1G93A mouse model of ALS, pyruvate
(1000mg/kg/week i.p.) slowed disease progression and also
improved motor symptoms in a rotarod test and survival by
10.5% when it was administered starting at the onset of disease
(Park et al., 2007). However, in a similar study performed to
evaluate the effects of pyruvate with increased frequency of
dosing (500mg/kg i.p., 6 days a week) in SOD1G93A mice,
pyruvate was not able to alter the onset of the disease or
survival of mice (Esposito et al., 2007). Esposito and colleagues
hypothesized that their higher levels of pyruvate may not lead to
larger benefit due to pyruvate’s U-shaped dose-response curve
(Esposito et al., 2007). The different outcomes may therefore
be explained by the use of different dosing and different mouse
strains.
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Lactate
Lactate is the end product of the glycolytic pathway (Rogatzki
et al., 2015) and also can be utilized as an energy fuel following
its conversion into pyruvate and subsequent oxidation in the
mitochondria (Schurr, 2008). Studies have demonstrated the role
of lactate as a neuroprotective energy substrate in brain disorders
such as cerebral ischemia (Schurr et al., 2001; Berthet et al.,
2009; Horn and Klein, 2013; Castillo et al., 2015) and traumatic
brain injury (TBI) (reviewed in Brooks and Martin, 2014;
Carpenter et al., 2015; Patet et al., 2016). Early administration
of lactate in rat organotypic hippocampal slices after oxygen-
glucose deprivation protected against neuronal death, decreased
lesion size and showed better neurologic outcomes in a mouse
model of middle cerebral artery occlusion (Berthet et al., 2009,
2012). Lactate has also been shown to provide neuroprotection
against glutamate mediated toxicity in rat hippocampal slices
(Schurr and Gozal, 2011), in mouse cortical neuron cultures
(Jourdain et al., 2016) and in rat cortex in vivo (Ros et al., 2001).
In addition, exogenous administration of lactate reduced brain
lesion size in a rat controlled cortical impact models of TBI
(Alessandri et al., 2012) and in patients with severe TBI (Bouzat
et al., 2014). Similarly, lactate infusion prevented intracranial
hypertensive episodes in patients with severe TBI (Ichai et al.,
2009, 2013; Bouzat et al., 2014), and attenuated cognitive deficits
in rat lateral fluid percussion injury (Rice et al., 2002; Holloway
et al., 2007) and in patients with mild TBI (Bisri et al., 2016).
The mechanism of lactate was linked to its ability to improve
cerebral energy metabolism and preserve ATP levels in injured
brain (Holloway et al., 2007; Gallagher et al., 2009; Bouzat
et al., 2014; Jourdain et al., 2016). In addition to its effect as
an energy fuel, lactate can function as a signaling molecule by
activating hydrocarboxylic acid receptor 1 (HCA1) receptors
(Castillo et al., 2015). ATP produced from lactate was also shown
to act on the P2Y receptors (Jourdain et al., 2016). Lactate
can be used either directly following its cerebral uptake or
indirectly as a gluconeogenic precursor (Glenn et al., 2015a,b).
Using lactate as an energy fuel for neurons with energy deficit
in diseases such as ALS may improve symptoms, especially if
reductions of astrocytic lactate transporters found in SOD1G93A
mice (Ferraiuolo et al., 2011) are not affecting neuronal lactate
uptake.
Creatine
Creatine is phosphorylated by ATP to phosphocreatine, which
is another high energy phosphate in addition to ATP. Sufficient
amounts of creatine are therefore important to prevent energy
depletion. It also stabilizes mitochondrial membranes by
binding to phospholipids (Persky and Brazeau, 2001). It has
demonstrated beneficial effects in treating energy impairments
in several neurodegenerative disorders such as Alzheimer’s
disease, Parkinson’s disease and Huntington’s disease (reviewed
by Adhihetty and Beal, 2008). Early studies in ALS showed that
administration of creatine to SOD1G93A mice prevented loss
of motor neurons, protected neurons from oxidative damage
in the spinal cord, and improved motor performance and
survival of mice in a dose dependent manner (Klivenyi et al.,
1999). Also, long term supplementation of creatine in SOD1G93A
mice was able to reduce NMDA induced release of glutamate
in the cerebral cortex (Andreassen et al., 2001b). Similarly,
treatment with creatine prevented depletion of ATP in spinal
cord and cerebral cortex of SOD1G93A mice (Browne et al., 2006).
Although preclinical studies were promising, several clinical
trials failed to show significant beneficial effects in improving
the progression of the disease or survival of patients (Groeneveld
et al., 2003; Shefner et al., 2004; Rosenfeld et al., 2008).
Coenzyme Q
Coenzyme Q is an electron acceptor in the electron transport
chain inmitochondria. It is a powerful antioxidant that scavenges
free radicals. Because of its effect in mitochondrial disorders,
coenzymeQ has been tried in the SOD1G93A mousemodel of ALS
(Matthews et al., 1998) and in patients with ALS (Kaufmann et al.,
2009). The idea is to promote activation of enzymes involved
in the electron transport chain which might be defected due to
reduced coenzyme Q in ALS. Coenzyme Q was neuroprotective
against 3-nitropropionic induced striatal lesions and it increased
the life span of SOD1G93A mice (Matthews et al., 1998). However,
the promising effects of Coenzyme Q in animal experiments were
not replicated in phase II clinical trials (Kaufmann et al., 2009).
MitoQ
MitoQ is an antioxidant which accumulates in mitochondria
(Kelso et al., 2001). It is a derivative of coenzyme Q that
promotes the uptake of endogenous coenzyme Q and improves
mitochondrial function (Tauskela, 2007). Cassina et al. (2008)
showed that mitochondrial function is impaired in the spinal
cords of symptomatic SOD1G93A rats, specifically mitochondrial
oxygen consumption by the electron transport chain. In
addition, SOD1G93A rat astrocytes showed signs of oxidative
stress. Therefore, they used MitoQ to target antioxidants to
the mitochondria. They demonstrated that pretreatment of
cultured SOD1G93A astrocytes with MitoQ was able to reduce
the formation of superoxide and peroxynitrite radicals, protect
motor neurons against oxidative damage and improve the
ability of mitochondria to generate ATP (Cassina et al., 2008).
Consistent with this, in a similar study in the SOD1G93A mouse
model, treatment with MitoQ at the onset of disease also
delayed the decline of mitochondrial function in the spinal cord,
protected against motor neuron loss and astrogliosis in the spinal
cord. Moreover, it preserved the integrity of the neuromuscular
junction, improved hind limb grip strength as well as the life span
of mice (Miquel et al., 2014), raising the hope that MitoQ may be
effective in ALS patients. On the other hand, in a study with 128
Parkinson’s Disease patients, 40 and 80mg MitoQ per day was
associated with dose-dependent increased incidence of nausea
and vomiting (Snow et al., 2010). Also, there was no change in
progression of disease on a Parkinson Disease Rating Scale.
Dexpramipexole
Dexpramipexole, an enantiomer of pramipexole, is believed to
increase ATP generation by improving efficiency of oxidative
phosphorylation as well as reducing oxidative damage of
mitochondria (Gribkoff and Bozik, 2008). In vitro studies
showed that it is able to promote metabolic efficiency of
injured cells and scavenging of free radicals in the mitochondria
(Danzeisen et al., 2006; Alavian et al., 2012). In another
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study, dexpramipexole prevented H2O2 mediated cell death
and prevented the generation of mitochondrial reactive oxygen
species in neuroblastoma cells (Ferrari-Toninelli et al., 2010). In
the SOD1G93A mouse model, dexpramipexole preserved motor
function and prolonged life span (Danzeisen et al., 2006). Due to
these beneficial effects in vitro and in vivo, dexpramipexole was
investigated in a double blind randomized phase 2 clinical trial
in patients with ALS, showing that treatment for 12 months was
safe and well tolerated (Cudkowicz et al., 2011). Dexpramipexole
also prevented functional decline in a dose dependent manner
compared to placebo (Cudkowicz et al., 2011). However, despite
the promising effects in this study, a phase 3 clinical trial
failed to show improvements in disease symptoms (Cudkowicz
et al., 2013). Dexpramipexole’s failure was linked to lack of
prior rigorous preclinical testing. Studies performed after the last
clinical trial, in induced pluripotent stem cells (iPSCs) derived
from patients with ALS (Yang et al., 2013), in rat primary cortical
neurons transfected with human mutant TDP-43 as well as in the
SOD1G93A mousemodel (Vieira et al., 2014) showed no beneficial
effect.
Acetyl-L-Carnitine
Acetyl-L-carnitine supplies L-carnitine, which is important in
the transport of long chain fatty acids across mitochondrial
membranes (Fritz and Yue, 1964). In addition, the acetyl moiety
can be transferred to provide acetyl CoA. Therefore, acetyl-L-
carnitine improves cerebral oxidative energy production (Zanelli
et al., 2005) and fatty acid oxidation in muscles (Siliprandi et al.,
1965). It has shown beneficial effects in models of traumatic
brain (Scafidi et al., 2010) and spinal cord injury (Zhang et al.,
TABLE 1 | Summary of metabolic approaches in ALS and their effects in models of ALS and patients with ALS.
Metabolic therapy Proposed mechanisms Effects on ALS models Effects on clinical trials
Acetyl-L-carnitine Provides acetyl-CoA, improves fatty
acid transport
Protected against kainate and NMDA toxicity in vitro (Bigini
et al., 2002)
Improved ALSFR scale in phase II
trial (Beghi et al., 2013)
Caprylic triglyceride Provides acetyl-CoA and ketones Delayed motor symptoms, prevented motor neuron loss, no
effect on survival (Zhao et al., 2012)
ND
Creatine Provides high energy phosphates and
stabilizes mitochondrial membranes
Prevented motor neuron loss, improved motor performance
and survival (Klivenyi et al., 1999)
Prevented ATP depletion in brain and spinal cord (Browne
et al., 2006)
Reduced glutamate increase (Andreassen et al., 2001a)
No efficacy in phase II-III clinical trials
(Groeneveld et al., 2003; Shefner
et al., 2004; Rosenfeld et al., 2008)
CoQ10 Antioxidant, improves mitochondrial
function
Neuroprotective in animal models, increased survival
(Matthews et al., 1998)
No efficacy in Phase II clinical trial
(Kaufmann et al., 2009)
Deanna protocol Provides acetyl-CoA, ketones and
α-KG
Delayed motor symptoms, increased survival (Ari et al.,
2014)
ND
Dexpramipexole Aid ATP generation Scavenge free
radicals
Improved motor function, prolonged survival (Danzeisen
et al., 2006)
Improved ALSFR scale in Phase II
clinical trial (Cudkowicz et al., 2011)
No benefit in Phase III clinical trial
(Cudkowicz et al., 2013)
Dichloroacetate Inhibits PDH kinase Delayed motor symptoms, prevented motor neuron loss,
increased survival (Miquel et al., 2012; Palamiuc et al.,
2015)
ND
Ketogenic diet Provides C4 ketones Delayed motor symptoms, no effect on survival (Zhao et al.,
2006)
ND
MitoQ Antioxidant, improves mitochondrial
function
Prevented motor neuron loss, improved motor function and
survival (Cassina et al., 2008; Miquel et al., 2014)
ND
Olesoxime Stabilizes mitochondrial permeability
transition pore
Delayed motor symptoms, increased survival (Bordet et al.,
2007)
No efficacy in phases II-III clinical
trials (Lenglet et al., 2014)
Pyruvate Provides acetyl-CoA, antioxidant Slowed motor symptoms, increased survival (Park et al.,
2007)
No effects on disease progression (Esposito et al., 2007)
ND
Triheptanoin Anaplerotic, provides acetyl-CoA,
propionyl CoA and C5 ketones
Delayed motor symptoms, prevented motor neuron loss
(Tefera et al., 2016)
ND
ND, not determined.
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2015), cerebral ischemia (Shuaib et al., 1995; Jalal et al., 2010),
stroke (Lolic et al., 1997) and Alzheimer’s disease (Virmani et al.,
2001) and patients with Alzheimer’s disease (Spagnoli et al., 1991;
Pettegrew et al., 1995). In primary motor neuron cultures from
rats, acetyl-L-carnitine was found to protect against kainate and
NMDA-induced toxicity (Bigini et al., 2002). In light of this, a
randomized double blind placebo-controlled trial was performed
in small number of patients with ALS to investigate the effects of
add-on acetyl-L-carnitine to riluzole vs. riluzole only treatment.
Patients tolerated the combination well and had a better score in
the ALS Functional Rating Scale (Beghi et al., 2013). More in vivo
studies in ALS models and a larger phase III trial are now needed
to prove efficacy.
Olesoxime
Olesoxime is an experimental compound believed to stabilize
mitochondrial permeability transition pores (Bordet et al., 2007).
In vitro studies showed increased motor neuron survival in a
motor neuron degeneration model in rats (Bordet et al., 2007). In
addition, treatment of SOD1G93A transgenic mice with olesoxime
improved motor function in the hanging grid test, delayed the
onset of body weight loss and prolonged survival by 10% (Bordet
et al., 2007). Olesoxime was also shown to delay denervation of
muscle and decrease activation of microglia and motor neuron
death in the lumbar spinal cord (Sunyach et al., 2012). However,
a phase II-III double blind, randomized, placebo-controlled
clinical trial failed to show efficacy in patients with ALS (Lenglet
et al., 2014). Similar to dexpramipexole, absence of rigorous
evaluation in preclinical studies may have led to its failure.
In iPSCs derived from patients with ALS, olesoxime showed
inconsistent effects (Yang et al., 2013).
Others
Other compounds that directly or indirectly affect energy
metabolism such as sirtuins prevent fragmentation of
mitochondria and promote an increase in ketone levels
and are potential therapeutic targets in ALS (Körner et al.,
2013a; Pasinetti et al., 2013). Resveratrol, an antioxidant, which
is believed to increase sirtuin 1 expression, was able to delay
onset of symptoms, prevent motor neuron loss and extend
survival when treatment was initiated at early stages of the
disease in hSOD1G93A mice (Mancuso et al., 2014; Song et al.,
2014). Moreover, dysregulation of AMP-activated protein kinase
(AMPK), an energy sensor which is induced by energy depletion
was also linked to ALS (reviewed in Perera and Turner, 2016).
AMPK was shown to be activated in TDP-43 mice spinal cord
(Perera et al., 2014) and reducing its activity prevented loss of
motor neurons in Caenorhabditis elegans models of ALS (Lim
et al., 2012). In general, substances that can counteract energy
depletion through modulation of the energy producing pathways
could help in delaying disease progression.
CONCLUSIONS
Of the metabolic approaches discussed above, creatine,
dexpramipexole, olesoxime, MitoQ and Coenzyme Q have
been investigated in randomized clinical trials (summarized in
Table 1). All failed to deliver beneficial effects except acetyl-
L-carnitine which showed improved ALS Functional Rating
Scale in small number of patients in a phase II clinical trial. The
effects of ketogenic diet, caprylic triglyceride, DCA, the Deanna
protocol and triheptanoin in patients with ALS remains to be
seen. It is critical to note that although numerous (around 50)
compounds have been investigated in randomized clinical trials,
almost all of them failed to show efficacy except riluzole, the
only approved drug so far (Mitsumoto et al., 2014). On the other
hand, analysis of preclinical therapeutic trials in hSOD1G93A
mouse model of ALS revealed that publication bias and poorly
designed experiments such as absence of randomization and
blinding, lack of adequate statistical power, and variations
within the animal models may lead to over reporting of false
positive results (Benatar, 2007; Scott et al., 2008; Perrin, 2014).
In addition, methodological flaws in clinical trials could also
lead to failure to find efficacy of treatments (Mitsumoto et al.,
2014). Therefore, it is of utmost importance to investigate future
potential treatments in adequately designed preclinical and
clinical trials.
In conclusion, many studies demonstrated that metabolic
disturbances are evident in patients with ALS and animal
models. Only, a few studies have investigated the effects of
metabolic treatments in ALS disease progression and survival.
The therapeutic effects of these compounds in animal models and
in vitro studies either in delaying motor symptoms, protecting
against motor neuron loss and/or improving survival suggest that
further studies should be performed to characterize abnormalities
in energy metabolism in ALS and explore potential metabolic
therapies.
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